表紙
市場調査レポート

医薬原薬 (API) の世界市場の予測 〜2020年:タイプ・合成タイプ・製造区分・疾患区分 (癌・糖尿病・整形外科・CNS・腎臓・眼科) 別

Active Pharmaceutical Ingredient Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech), Type of Manufacturer (Captive, Merchant), Therapy (Oncology, Diabetes, Orthopedic, CNS, Nephrology, Ophthalmology) - Global Forecast to 2020

発行 MarketsandMarkets 商品コード 225648
出版日 ページ情報 英文 208 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
医薬原薬 (API) の世界市場の予測 〜2020年:タイプ・合成タイプ・製造区分・疾患区分 (癌・糖尿病・整形外科・CNS・腎臓・眼科) 別 Active Pharmaceutical Ingredient Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech), Type of Manufacturer (Captive, Merchant), Therapy (Oncology, Diabetes, Orthopedic, CNS, Nephrology, Ophthalmology) - Global Forecast to 2020
出版日: 2015年10月28日 ページ情報: 英文 208 Pages
概要

世界の医薬原薬 (API) 市場の成長は、生活習慣病や加齢に起因する疾患の発症率の増加、癌の有病率の拡大、API製造における技術的進歩、新しいバイオシミラー市場、高活性有効成分の有望性の拡大などによって推進されています。一方で、厳しい法規制上のガイドラインや世界的な不況が予測期間中の市場成長を妨げる可能性があります。

当レポートでは、世界の医薬原薬 (API) の市場について調査し、APIおよび高薬理活性API (HPAPI) の概要、市場成長の推進因子・阻害因子、市場機会の分析、薬剤区分・合成区分・製造区分・疾患区分などの各種区分別の市場規模の推移と予測、地域および主要国における動向、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • タイプ別市場
  • 疾患区分別市場
  • 合成タイプ別市場
  • 製造区分別市場
  • 地域概要
  • タイプ別HPAPI市場
  • 合成タイプ別HPAPI市場
  • 製造タイプ別HPAPI市場
  • 地域別HPAPI市場

第5章 市場概要

  • イントロダクション
  • 市場区分
    • タイプ別
    • 合成タイプ別
    • 製造タイプ別
    • 疾患区分別
    • 地域別
  • 市場動態
    • 市場推進要因
    • 市場抑制要因
    • 市場機会
    • 課題

第6章 市場分析:合成区分別

  • 合成によるAPI
  • タイプ別
    • 革新的合成API
    • ジェネリック合成API
  • バイオ技術によるAPI
    • 製品別
    • タイプ別
    • 革新的バイオテックAPI
    • バイオジェネリクス/バイオシミラー

第7章 市場分析:製造タイプ別

  • イントロダクション
  • 自社用API製造
  • 販売用API製造
    • タイプ別
      • 革新的API
      • ジェネリックAPI

第8章 市場分析:タイプ別

  • イントロダクション
  • 革新的API
  • ジェネリックAPI

第9章 市場分析:疾患区分別

  • 糖尿病
  • 心臓血管系疾患
  • CNS・神経系疾患
  • 整形外科系
  • 腎臓
  • 眼科
  • 呼吸器科
  • 胃腸疾患
  • 内分泌系

第10章 高薬理活性API (HPAPI) 市場

  • イントロダクション
    • HPAPIの分類
    • 概要:世界のHPAPI市場
    • 製造能力
      • ハンドリング要件
      • 人材
      • 工場・機器
      • 技術
  • HPAPI市場の分析:製品別
    • HPAPI市場:タイプ別
      • 革新的HPAPI
      • ジェネリックHPAPI
  • HPAPI市場の分析:製造タイプ別
    • 自社用HPAPI
    • 販売用HPAPI
  • HPAPI市場の分析:合成手法別

第11章 市場分析:地域別

  • イントロダクション
  • PEST分析
  • 北米
    • API市場
    • 高薬理活性API市場
    • 米国
      • API市場
      • 高薬理活性API市場
    • カナダ
      • API市場
      • 高薬理活性API市場
  • 欧州
    • API市場
    • 高薬理活性API市場
    • 英国
      • API市場
      • 高薬理活性API市場
    • フランス
      • API市場
      • 高薬理活性API市場
    • ドイツ
      • API市場
      • 高薬理活性API市場
    • スペイン
      • API市場
      • 高薬理活性API市場
    • イタリア
      • API市場
      • 高薬理活性API市場
    • その他
      • API市場
      • 高薬理活性API市場
  • アジア
    • API市場
    • 高薬理活性API市場
    • インド
      • API市場
      • 高薬理活性API市場
    • 日本
      • API市場
      • 高薬理活性API市場
    • 韓国
      • API市場
      • 高薬理活性API市場
    • 中国
      • API市場
      • 高薬理活性API市場
    • その他
      • API市場
      • 高薬理活性API市場
  • その他
    • API市場
    • 高薬理活性API市場

第12章 競合環境

  • 競合状況・動向
    • 新製品の投入
    • M&A
    • 提携・合意・協力・ジョイントベンチャー
    • 拡張

第13章 企業プロファイル

  • イントロダクション
  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED
  • DR. REDDY'S LABORATORIES LTD.
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • AUROBINDO PHARMA LTD.
  • NOVARTIS INTERNATIONAL AG
  • ALBEMARLE CORPORATION
  • SIGMA-ALDRICH CORPORATION
  • MYLAN INC.
  • ALLERGAN PLC
  • BOEHRINGER INGELHEIM
    • 事業概要
    • 製品・サービス
    • 戦略
    • 発展動向、など

第14章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PH 1262

The Active Pharmaceutical Ingredients market is categorized on the basis of type, type of manufacturer, type of synthesis, therapeutic area and region. Factors such as increasing incidence of life style and age related diseases, Increasing prevalence of cancer across the world, Technological advancements in the APIs Manufacturing, Emerging markets for biosimilars and increasing scope for Highly potent active ingredients are driving market growth. On the other hand, stringent regulatory guidelines and global economic recession may restrict market growth in the forecast period.

North America accounts for the highest share of the global APIs market. The overall technological advancements in this region coupled with factors like increase in lifestyle and age related disorders in this region, the increase in demand for specialty biological and specialty drugs and increasing government focus on generics following the implementation of the Patient Protection and Affordable Care Act is driving the growth of this market.

Apart from the comprehensive geographical analysis, product analysis, and market sizing, the report also provides a competitive landscape that covers growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise basic views on key players and their product portfolios, developments, and strategies adopted. The abovementioned market research data, current market sizes, and forecast of future trends will help key players and new entrants make informed decisions regarding product offerings, geographical focus, and change in strategic approach; R&D investments; and levels of output in order to remain successful.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms, garner a greater market share. Firms purchasing the report can use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration:Comprehensive information on the product portfolios of top players in the APIs market. The report analyzes the APIs and HPAPIs market by type, type of synthesis, type of manufacturer, therapeutic area and region.
  • Product Development/Innovation:Detailed insights on upcoming technologies, R&D activities, and new product launches in the APIs market
  • Competitive Assessment:In-depth assessment of market strategies, geographical and business segments, and product portfolios of the leading players in APIs market
  • Market Development:Comprehensive information about lucrative emerging markets. The report analyzes the market for APIs across geographies
  • Market Diversification:Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the APIs market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. LIMITATIONS
  • 1.5. CURRENCY
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY RESEARCH
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY RESEARCH
      • 2.1.2.1. Key data from primary sources
      • 2.1.2.2. Key industry insights
      • 2.1.2.3. Breakdown of primaries
  • 2.2. MARKET SIZE ESTIMATION
    • 2.2.1. BOTTOM-UP APPROACH
    • 2.2.2. TOP DOWN APPROACH
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4. RESEARCH ASSUMPTIONS AND LIMITATIONS
    • 2.4.1. ASSUMPTIONS
    • 2.4.2. LIMITATIONS

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
  • 4.2. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC AREA
  • 4.3. ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF SYNTHESIS
  • 4.4. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER
  • 4.5. GEOGRAPHIC SNAPSHOT OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  • 4.6. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
  • 4.7. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS
  • 4.8. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER
  • 4.9. GEOGRAPHIC SNAPSHOT OF THE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
    • 5.2.1. BY TYPE
    • 5.2.2. MARKET SEGMENTATION, BY TYPE OF SYNTHESIS
    • 5.2.3. MARKET SEGMENTATION, BY TYPE OF MANUFACTURER
    • 5.2.4. MARKET SEGMENTATION, BY THERAPEUTIC AREA
    • 5.2.5. MARKET SEGMENTATION, BY REGION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. Increasing incidence of lifestyle and age-related diseases
      • 5.3.1.2. Rising cancer prevalence across the globe
      • 5.3.1.3. Technological advancements in API manufacturing
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. Stringent regulatory requirements
      • 5.3.2.2. Economic recession
    • 5.3.3. OPPORTUNITIES
      • 5.3.3.1. Emerging biosimilars market
      • 5.3.3.2. Increasing scope for highly potent active pharmaceutical ingredients
    • 5.3.4. CHALLENGES
      • 5.3.4.1. Product differentiation - A major concern for API manufacturers

6. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY SYNTHESIS

    • 6.1.1. SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS
    • 6.1.2. SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE
      • 6.1.2.1. Innovative Synthetic APIs
      • 6.1.2.2. Generic Synthetic APIs
    • 6.1.3. BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS
      • 6.1.3.1. Biotech APIs Market, by Product
        • 6.1.3.1.1. Monoclonal Antibodies
        • 6.1.3.1.2. Recombinant Proteins
        • 6.1.3.1.3. Vaccines
      • 6.1.3.2. Biotech APIs Market, by Type
        • 6.1.3.2.1. Innovative Biotech APIs
        • 6.1.3.2.2. Biogenerics/Biosimilars

7. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER

  • 7.1. INTRODUCTION
  • 7.2. CAPTIVE API MANUFACTURERS
  • 7.3. MERCHANT API MANUFACTURERS
    • 7.3.1. MERCHANT API MANUFACTURERS MARKET, BY TYPE
      • 7.3.1.1. Innovative APIs
      • 7.3.1.2. Generic APIs

8. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE

  • 8.1. INTRODUCTION
  • 8.2. INNOVATIVE APIS SEGMENT
  • 8.3. GENERIC APIS SEGMENT

9. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC AREA

  • 9.1. ONCOLOGY
  • 9.2. DIABETES
  • 9.3. CARDIOVASCULAR DISEASE
  • 9.4. CNS AND NEUROLOGICAL DISORDERS
  • 9.5. ORTHOPEDIC DISORDERS
  • 9.6. NEPHROLOGY
  • 9.7. OPHTHALMOLOGY
  • 9.8. PULMONOLOGY
  • 9.9. GASTROINTESTINAL DISORDERS
  • 9.10. ENDOCRINOLOGY

10. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

  • 10.1. INTRODUCTION
    • 10.1.1. HPAPI CLASSIFICATION
    • 10.1.2. OVERVIEW: HPAPI GLOBAL MARKET
    • 10.1.3. MANUFACTURING CAPABILITIES
      • 10.1.3.1. Handling requirements
      • 10.1.3.2. Personnel considerations
      • 10.1.3.3. Plant and equipment
      • 10.1.3.4. Technology
  • 10.2. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT
    • 10.2.1. HPAPI MARKET, BY TYPE
      • 10.2.1.1. INNOVATIVE HPAPI
      • 10.2.1.2. GENERIC HPAPI
  • 10.3. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER
      • 10.3.1.1. CAPTIVE HPAPI SECTOR
      • 10.3.1.2. MERCHANT HPAPI SECTOR
  • 10.4. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY METHOD OF SYNTHESIS

11. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION

  • 11.1. INTRODUCTION
  • 11.2. PEST ANALYSIS
    • 11.2.1. POLITICAL FACTORS
    • 11.2.2. ECONOMICAL FACTORS
    • 11.2.3. SOCIAL FACTORS
    • 11.2.4. TECHNOLOGICAL FACTORS
  • 11.3. NORTH AMERICA
    • 11.3.1. NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.3.2. NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.3.3. U.S.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.3.4. U.S.: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.3.5. CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.3.6. CANADA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  • 11.4. EUROPE
    • 11.4.1. EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.4.2. EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.4.3. U.K.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.4.4. U.K.: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.4.5. FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.4.6. FRANCE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.4.7. GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.4.8. GERMANY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.4.9. SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.4.10. SPAIN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.4.11. ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.4.12. ITALY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.4.13. ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.4.14. ROE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  • 11.5. ASIA
    • 11.5.1. ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.5.2. ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.5.3. INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.5.4. INDIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.5.5. JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.5.6. JAPAN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.5.7. SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.5.8. SOUTH KOREA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.5.9. CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.5.10. CHINA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.5.11. ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.5.12. ROA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  • 11.6. ROW
    • 11.6.1. ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • 11.6.2. ROW: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

12. COMPETITIVE LANDSCAPE

  • 12.1. COMPETITIVE SITUATION AND TRENDS
    • 12.1.1. NEW PRODUCT LAUNCHES
    • 12.1.2. MERGERS AND ACQUISITIONS
    • 12.1.3. PARTNERSHIPS, AGREEMENTS, COLLABORATIONS, AND JOINT VENTURES
    • 12.1.4. EXPANSION

13. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 13.1. INTRODUCTION
  • 13.2. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
  • 13.3. DR. REDDY'S LABORATORIES LTD.
  • 13.4. SUN PHARMACEUTICAL INDUSTRIES LTD.
  • 13.5. AUROBINDO PHARMA LTD.
  • 13.6. NOVARTIS INTERNATIONAL AG
  • 13.7. ALBEMARLE CORPORATION
  • 13.8. SIGMA-ALDRICH CORPORATION
  • 13.9. MYLAN INC.
  • 13.10. ALLERGAN PLC
  • 13.11. BOEHRINGER INGELHEIM

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

14. APPENDIX

  • 14.1. INSIGHTS FROM INDUSTRY EXPERTS
  • 14.2. DISCUSSION GUIDE
  • 14.3. OTHER DEVELOPMENTS, BY COMPANY, 2012-2015
  • 14.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 14.5. AVAILABLE CUSTOMIZATIONS
  • 14.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 2: GLOBAL SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 3: NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 4: EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 5: ASIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 6: GLOBAL SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 7: GLOBAL BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 8: NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 9: EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 10: ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 11: GLOBAL BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
  • TABLE 12: GLOBAL BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 13: GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2013-2020 (USD BILLION)
  • TABLE 14: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CAPTIVE MANUFACTURERS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 15: NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CAPTIVE MANUFACTURERS, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 16: EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CAPTIVE MANUFACTURERS, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 17: ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CAPTIVE MANUFACTURERS, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 18: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR MERCHANT MANUFACTURERS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 19: NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR MERCHANT MANUFACTURERS, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 20: EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR MERCHANT MANUFACTURERS, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 21: ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR MERCHANT MANUFACTURERS, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 22: GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR MERCHANT MANUFACTURERS, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 23: GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 24: PATENTS EXPIRIES, 2015
  • TABLE 25: GLOBAL GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 26: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC AREA, 2013-2020 (USD BILLION)
  • TABLE 27: CANCER: ESTIMATED INCIDENCE, MORTALITY, AND PREVALENCE (2012)
  • TABLE 28: REGIONAL ESTIMATES FOR DIABETES (2013)
  • TABLE 29: U.S.: LEADING RESPIRATORY DRUGS, 2014
  • TABLE 30: GLOBAL HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 31: NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 32: EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 33: ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 34: GLOBAL HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 35: GLOBAL GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 36: NORTH AMERICA: GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 37: EUROPE: GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 38: ASIA: GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 39: GLOBAL HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2013-2020 (USD BILLION)
  • TABLE 40: GLOBAL CAPTIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 41: NORTH AMERICA: CAPTIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 42: EUROPE: CAPTIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 43: ASIA: CAPTIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 44: GLOBAL MERCHANT HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 45: NORTH AMERICA: MERCHANT HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 46: EUROPE: MERCHANT HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 47: ASIA: MERCHANT HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 48: GLOBAL MERCHANT HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 49: GLOBAL HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 50: GLOBAL SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 51: NORTH AMERICA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 52: EUROPE: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 53: ASIA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 54: GLOBAL SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 55: GLOBAL BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 56: NORTH AMERICA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 57: EUROPE: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 58: ASIA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 59: GLOBAL BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 60: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 61: NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 62: EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 63: ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 64: NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 65: U.S.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 66: U.S.: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
  • TABLE 67: U.S.: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 68: CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 69: CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
  • TABLE 70: CANADA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 71: EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 72: U.K.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 73: U.K.: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 74: U.K.: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 75: FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 76: FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
  • TABLE 77: FRANCE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 78: GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 79: GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
  • TABLE 80: GERMANY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 81: SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 82: SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
  • TABLE 83: SPAIN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 84: ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 85: ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
  • TABLE 86: ITALY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 87: ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 88: ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
  • TABLE 89: ROE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 90: ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 91: INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 92: INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
  • TABLE 93: INDIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 94: JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 95: JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
  • TABLE 96: JAPAN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 97: SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 98: SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
  • TABLE 99: SOUTH KOREA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 100: CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 101: CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
  • TABLE 102: CHINA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 103: ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 104: ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
  • TABLE 105: ROA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
  • TABLE 106: ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
  • TABLE 107: ROW: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
  • TABLE 108: NEW PRODUCT LAUNCHES
  • TABLE 109: MERGERS AND ACQUISITIONS
  • TABLE 110: PARTNERSHIPS, AGREEMENTS, COLLABORATIONS, AND JOINT VENTURES
  • TABLE 111: EXPANSIONS
  • TABLE 112: SUN PHARMACEUTICALS INDUSTRIES LTD.
  • TABLE 113: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
  • TABLE 114: DR. REDDY'S LABORATORIES
  • TABLE 115: AUROBINDO PHARMA
  • TABLE 116: NOVARTIS
  • TABLE 117: BOEHRINGER INGELHEIM
  • TABLE 118: ALBEMARLE CORPORATION
  • TABLE 119: SIGMA-ALDRICH
  • TABLE 120: MYLAN INC.
  • TABLE 121: ALLERGAN PLC.

LIST OF FIGURES

  • FIGURE 1: GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: BOTTOM-UP APPROACH
  • FIGURE 4: TOP-DOWN APPROACH
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: API MARKET, BY TYPE (2015 VS. 2020): THE INNOVATIVE API SEGMENT TO DOMINATE MARKET IN THE FORECAST PERIOD
  • FIGURE 7: CAPTIVE MANUFACTURERS SEGMENT TO HOLD LARGEST MARKET SIZE IN 2015
  • FIGURE 8: SYNTHETIC APIS SEGMENT TO COMMAND LARGEST MARKET SIZE IN 2015
  • FIGURE 9: ONCOLOGY SEGMENT TO FORM LARGEST MARKET SHARE IN 2015
  • FIGURE 10: API MARKET, BY REGION: NORTH AMERICA TO COMMAND LARGEST SHARE IN 2015
  • FIGURE 11: HPAPI MARKET, BY TYPE (2015 VS. 2020): THE INNOVATIVE HPAPI SEGMENT TO DOMINATE MARKET IN THE FORECAST PERIOD
  • FIGURE 12: HPAPI MARKET, BY TYPE OF MANUFACTURER (2015 VS. 2020): THE CAPTIVE APIS SEGMENT TO DOMINATE MARKET IN THE FORECAST PERIOD
  • FIGURE 13: HPAPI MARKET, BY MODE OF SYNTHESIS (2015 VS. 2020): SYNTHETIC APIS TO DOMINATE MARKET IN THE FORECAST PERIOD
  • FIGURE 14: HPAPI MARKET, BY REGION: NORTH AMERICA TO COMMAND LARGEST SHARE IN 2015
  • FIGURE 15: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS OFFER HIGH GROWTH OPPORTUNITIES
  • FIGURE 16: THE ONCOLOGY SEGMENT TO ACCOUNT FOR THE LARGEST SIZE OF THE MARKET (2015-2020)
  • FIGURE 17: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS TO COMMAND THE LARGEST SHARE IN 2015
  • FIGURE 18: MERCHANT MANUFACTURERS SEGMENT TO GROW AT THE HIGHEST RATE FROM 2015 TO 2020
  • FIGURE 19: THE ASIAN REGION TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 20: GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS OFFER HIGH GROWTH OPPORTUNITIES
  • FIGURE 21: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS TO COMMAND THE LARGEST SHARE IN 2015
  • FIGURE 22: THE MERCHANT MANUFACTURERS SEGMENT TO GROW AT THE HIGHEST RATE FROM 2015 TO 2020
  • FIGURE 23: ASIA TO WITNESS HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 24: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION, BY TYPE
  • FIGURE 25: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION, BY TYPE OF SYNTHESIS
  • FIGURE 26: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION, BY TYPE OF MANUFACTURER
  • FIGURE 27: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION, BY THERAPEUTIC AREA
  • FIGURE 28: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION, BY REGION
  • FIGURE 29: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 30: SYNTHETIC CHEMICAL ACTIVE PHARMACEUTICAL INGREDIENTS TO DOMINATE THE GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN THE FORECAST PERIOD (2015-2020)
  • FIGURE 31: NORTH AMERICA IS THE LARGEST SEGMENT OF THE GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN THE FORECAST PERIOD (2015-2020)
  • FIGURE 32: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD (2015-2020)
  • FIGURE 33: RECOMBINANT PROTEINS TO DOMINATE THE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN THE FORECAST PERIOD (2015-2020)
  • FIGURE 34: NORTH AMERICA TO FORM THE LARGEST SEGMENT OF THE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN THE FORECAST PERIOD (2015-2020)
  • FIGURE 35: THE MERCHANT API MANUFACTURERS SEGMENT TO OFFER SIGNIFICANT GROWTH OPPORTUNITIES IN THE FORECAST PERIOD
  • FIGURE 36: CAPTIVE API MANUFACTURERS MARKET, BY REGION: ROW TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 37: MERCHANT API MANUFACTURERS MARKET, BY REGION: ASIA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 38: GENERIC APIS TO WITNESS HIGHER GROWTH RATE
  • FIGURE 39: GENERIC ACTIVE PHARMACEUTICALS MARKET, BY REGION: ASIA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD (2015-2020)
  • FIGURE 40: ONCOLOGY TO DOMINATE THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN THE FORECAST PERIOD
  • FIGURE 41: NORTH AMERICAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
  • FIGURE 42: EUROPEAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
  • FIGURE 43: KEY PLAYERS MAJORLY ADOPTED INORGANIC GROWTH STRATEGIES BETWEEN 2012 AND 2015
  • FIGURE 44: MARKET EVOLUTION FRAMEWORK -2014 WAS THE MOST ACTIVE YEAR DURING THE STUDIED PERIOD
  • FIGURE 45: BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS BETWEEN 2012 AND 2015
  • FIGURE 46: GEOGRAPHIC REVENUE MIX FOR THE TOP 5 PLAYERS IN THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  • FIGURE 47: TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • FIGURE 48: DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
  • FIGURE 49: SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • FIGURE 50: AUROBINDO PHARMA LTD.: COMPANY SNAPSHOT
  • FIGURE 51: NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT
  • FIGURE 52: ALBEMARLE CORPORATION: COMPANY SNAPSHOT
  • FIGURE 53: SIGMA-ALDRICH CORPORATION: COMPANY SNAPSHOT
  • FIGURE 54: MYLAN INC.: COMPANY SNAPSHOT
  • FIGURE 55: ALLERGAN PLC.: COMPANY SNAPSHOT
  • FIGURE 56: BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
Back to Top